Our Take
Indiana's biotech edge is real but fragile: it rests almost entirely on Lilly's continued dominance in GLP-1s, not on structural advantages that would survive a shift in pharma priorities.
Why it matters
States are now explicitly competing for biopharma investment, and Indiana's strategy—built on one company's momentum—reveals both the leverage and the risk of regional clustering. Practitioners in biotech talent, supply chain, and real estate need to watch whether this holds beyond Lilly's current blockbuster cycle.
Do this week
Biotech supply-chain leaders: audit your Lilly concentration in the next 30 days. Map which tiers of your Indiana operations depend on a single customer's revenue trajectory, not multi-customer resilience.
Lilly's $21B Indiana investment anchors state biotech ambitions
Indiana unveiled BioHeartland Indiana at the 2026 BIO International Convention, a rebranded collective combining BioCrossroads (a 25-year-old life sciences partnership), corporate partners, and agri-bioscience groups. The state is competing directly with California, Massachusetts, New York, Texas, and others for pharma manufacturing and R&D investment.
Eli Lilly, headquartered in Indiana, has invested $21bn in the state since 2020, with a $4.5bn announcement last month for Lebanon facility expansion (active pharmaceutical ingredient production and genetic medicines manufacturing). Lilly's 2025 sales grew 45% to $65.2bn, driven by tirzepatide (Mounjaro, Zepbound) GLP-1 revenues (company-reported).
The state is also benefiting from federal backing. Indiana's Heartlands BioWorks received over $51m from the 2022 Chips & Science Act, with approximately $30m allocated to a biomanufacturing training facility opening fall 2027. The facility will focus on large-molecule upstream and downstream manufacturing workforce development.
The broader Indiana life sciences sector employs more than 70,000 people. Beyond Lilly, the state is home to animal health leader Elanco and plant science company Corteva.
One company's success story masks structural vulnerability
Vince Wong, president and CEO of BioCrossroads, positioned Indiana's advantage as integration across human, animal, and plant health (the "one health" concept), plus a complete value chain from invention through manufacturing and logistics. That pitch is credible. But the numbers tell a different story.
Lilly's $21bn investment and 45% sales growth are funding the entire ecosystem through three channels: direct Lilly expansion, spillover growth to tier-one suppliers, and philanthropy. Lilly Endowment, the nation's largest private foundation (bigger than Gates, per Wong), focuses a high percentage of its charitable assets in Indiana precisely because it holds the majority of its portfolio in Lilly stock. This creates a structural feedback loop: Lilly stock price and earnings directly determine Indiana's philanthropic and economic momentum.
The state's differentiation claim—one-health expertise and a closed-loop value chain—is generic enough to describe a dozen regions. What actually differentiates Indiana is Lilly's continued blockbuster performance in GLP-1s, a market segment that has already attracted billions in competing R&D from Novo Nordisk, Roche, Viking Therapeutics, and others. If Lilly's growth plateaus or if GLP-1 competition intensifies price pressure, Indiana's relative advantage shrinks immediately.
The $51m federal investment in workforce training is a hedge, not a foundation. Training 2,000 biomanufacturers by 2028 is useful only if multistate demand exists to absorb them.
Who needs to pay attention and when
Biotech supply-chain operators: if your revenue concentration from Lilly (direct or indirect) exceeds 40%, you are exposed to a single company's R&D calendar and commercial momentum. GLP-1 market saturation timelines vary, but reimbursement pressure is building globally.
Talent acquisition teams recruiting from Indiana should expect rising compensation expectations tied to Lilly's continued hiring spree. If Lilly's growth stalls, wage inflation in the region could become a liability rather than a recruiting advantage.
Real estate and site-selection teams evaluating Midwest biopharma clusters should treat Indiana as a short-to-medium-term (3–5 year) play, not a multi-decade anchor. The state's success is reproducible elsewhere (Massachusetts and California have already done it), and Lilly's moat in GLP-1s is pharmacology-dependent, not geography-dependent.